Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Otsuka Holdings CoFRA:OS1 -0.77%87 EV-to-OCF is 14.75 as of Aug. 25, 2026, which is 27% above its 10-year median of 11.63. GuruFocus rates FRA:OS1 with a GF Score™ of 87/100 and a GF Value™ of €48.97 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Otsuka Holdings Co ranks worse than 60.2% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Otsuka Holdings Co's Enterprise Value is €33,237 Mil.
Otsuka Holdings Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €2,253 Mil. Therefore, Otsuka Holdings Co's EV-to-OCF for today is 14.75.
The historical rank and industry rank for Otsuka Holdings Co's EV-to-OCF or its related term are showing as below:
FRA:OS1'
s EV-to-OCF Range Over the Past 10 Years
Min: 7.69 Med: 11.63 Max: 31.43
Current: 15.11
During the past 13 years, the highest EV-to-OCF of Otsuka Holdings Co was 31.43. The lowest was 7.69. And the median was 11.63.
FRA:OS1's EV-to-OCF is ranked worse than 60.2% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.77
vs FRA:OS1: 15.11
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Otsuka Holdings Co (FRA:OS1) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Otsuka Holdings Co's PE Ratio (TTM) for today is calculated as:
Otsuka Holdings Co's share price for today is €64.50.
Otsuka Holdings Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Otsuka Holdings Co EV-to-OCF Related Terms
Otsuka Holdings Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Otsuka Holdings Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Otsuka Holdings Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otsuka Holdings Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Otsuka Holdings Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Otsuka Holdings Co's EV-to-OCF falls into.
Otsuka Holdings Co's current Enterprise Value is €33,237 Mil.
Otsuka Holdings Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,253 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otsuka Holdings Co (FRA:OS1) has a EV-to-OCF of 14.75 as of Aug. 25, 2026. This is 27% above median its historical median of 11.63. Over the past decade, Otsuka Holdings Co's EV-to-OCF has ranged from 7.69 to 31.43. According to the industry distribution chart, Otsuka Holdings Co ranks #605 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 60.2%.
Is Otsuka Holdings Co's EV-to-OCF too high?
Otsuka Holdings Co's current EV-to-OCF of 14.75 is 27% above median its 10-year median of 11.63. Over the past 10 years, this metric has ranged from a low of 7.69 to a high of 31.43. The Drug Manufacturers industry median EV-to-OCF is 10.77. Otsuka Holdings Co's value of 14.75 is 37% above this industry median. Based on the distribution chart, Otsuka Holdings Co ranks #605 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Otsuka Holdings Co has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Otsuka Holdings Co's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Otsuka Holdings Co ranks #605 out of 1005 companies for EV-to-OCF. This places Otsuka Holdings Co in the lower half of its industry. The industry median EV-to-OCF is 10.77. Otsuka Holdings Co's value of 14.75 is 37% above this benchmark. Historically, Otsuka Holdings Co's own EV-to-OCF has ranged from 7.69 to 31.43 over the past decade. While the company's 10-year median is 11.63 vs. the industry median of 10.77, Otsuka Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.77, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Otsuka Holdings Co's current EV-to-OCF of 14.75 is 37% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Otsuka Holdings Co's current EV-to-OCF is 14.75, which is 27% above median its own 10-year median of 11.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otsuka Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Otsuka Holdings Co (FRA:OS1) is currently considered Significantly Overvalued. The stock's GF Value™ is €48.97, compared to a current price of €64.50 — trading 31.7% above its estimated fair value. The current EV-to-OCF is 14.75, which is 27% above median its 10-year median of 11.63 and 37% above the Drug Manufacturers industry median of 10.77. Otsuka Holdings Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Otsuka Holdings Co (FRA:OS1), the current EV-to-OCF is 14.75 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Otsuka Holdings Co (FRA:OS1) Overvalued in 2026?
Based on GuruFocus' analysis, Otsuka Holdings Co stock appears to be overvalued.
The current stock price of €64.50 is trading 31.7% above its estimated GF Value™ of €48.97.
GuruFocus considers Otsuka Holdings Co to be Significantly Overvalued.
Key valuation signals for FRA:OS1:
EV-to-OCF: 14.75 (27% above median its 10-year median of 11.63)
GF Value™: €48.97 vs. price of €64.50 (31.7% above fair value)
Industry Position: 37% above the Drug Manufacturers median (#605 of 1005)
No single metric tells the full story. See the FRA:OS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Otsuka Holdings Co Ltd is a Japan-based company that operates in pharmaceuticals, nutraceuticals, and consumer products. It operates through four reportable segments: Medical-related Business, Nutraceutical-related Business, Consumer-related Business, and Other Business. The Medical Business manufactures and sells therapeutic drugs and infusions, the Nutraceutical Business produces functional foods, beverages, and nutritional supplements, the Consumer Business offers mineral water, beverages, and foods, while the Other Business provides storage services and manufactures chemicals and analytical equipment. It generates the majority of its revenue from the medical-related business segment.
87GF Score
Get the complete analysis for FRA:OS1
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OS1 has been successfully added to your 
